Freeze-dried and GMP-compliant pharmaceuticals containing exosomes for acellular mesenchymal stromal cell immunomodulant therapy. (11th February 2019)

• Record Type: Journal Article
• Authors: Bari, Elia; Perteghella, Sara; Catenacci, Laura; Sorlini, Marzio; Croce, Stefania; Mantelli, Melissa; Avanzini, Maria A; Sorrenti, Milena; Torre, Maria L
• Is Part Of: Nanomedicine. Volume 14:Number 6(2019)
• Page Start: 753
• Page End: 765
• Publication Date: 2019-02-11
• Subjects: adipose tissue -- bone marrow -- exosome -- extracellular vesicles -- freeze-drying -- immunomodulation -- mesenchymal stromal cells -- secretome -- ultracentrifugation -- ultrafiltration; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2018-0240
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: To validate the use of ultrafiltration (UF) as an alternative applicable industrial method to replace ultracentrifugation (UC) in the purification of mesenchymal stromal cell (MSC)-secretome.Materials & methods: Pharmaceutical formulations containing secretome and/or extracellular vesicles were extracted from adipose-MSCs and bone marrow-MSCs by combining UF or UC with lyophilization.Results & conclusion: UF led to higher protein, lipid, cytokine and exosomes yields compared with UC. The isolation procedure and cell source influenced immunomodulatory activity, which was in vitro evaluated by inhibition of phytohemagglutinin-activated peripheral blood mononuclear cell proliferation, and by modulation of IL-10, IFN-γ and IL-6. A secretome dosage was identified to obtain the same immunomodulatory activity of MSCs, paving the way for cell-free therapy.